UNSPSC 51101906: Proguanil

This classification denotes a dihydrofolate reductase inhibitor and antimalarial agent with the molecular formula C11H16ClN5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S61K3P7B2V, chemically known as sn 12,837 but generally known as chlorguanide, which bears US NIH Compound Identifier 6178111. European Medicines Agency schedules Proguanil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10079MIG.

UNSPSC 51101906 Proguanil (Commodity) shows minimal alignment with state and local procurement activity currently in the market. The recent opportunities tagged to this code involve naloxone and safe drug deactivation systems (Seminole County, Florida) and antibiotics including doxycycline and ciprofloxacin (Illinois Department of Public Health via MMCAP Infuse consortium), neither of which is proguanil, an antimalarial medication used primarily in travelers and at-risk populations. The mismatch suggests either miscoding in the state and local contracting database or that proguanil-specific procurement is not being conducted through these channels at present.

The Illinois opportunity was a completed award rather than an open solicitation—a $2,999,999.11 contract over three years to Chartwell Rx LLC for antibiotics through an Invitation for Bid process under the MMCAP Infuse cooperative purchasing vehicle, issued August 28, 2026. The Seminole County opportunity, posted June 30, 2026 with a July 26 response deadline, requested naloxone and drug deactivation systems annually. Neither opportunity represents an active pursuit path for proguanil supply. State and local procurement under this code does not currently show substantive recent activity aligned with the commodity's nominal scope.